Estrogen and cancers of the colorectum, breast, and lung in postmenopausal women

As estrogens play an important role in maintaining physiological function in various organs, the estrogen decrease after menopause is thought to cause various diseases frequently observed in postmenopausal or elderly women. With the aging of society and a decrease in infectious or vascular diseases, neoplasms have now become the most frequent cause of death in Japan. Cancers of the colorectum, breast, and lung have been rapidly increasing both in incidence and death, especially among postmenopausal women. Interestingly, all three of these cancers are associated with estrogens. In premenopausal women, ovarian estrogens plays major roles in the female reproductive organs through the classic estrogen receptor, ER‐α. In postmenopausal women, however, estrogens produced/activated by peripherally localized estrogen‐metabolizing enzymes such as aromatase, which converts androgen into estrogens, are thought to play physiologically and pathobiologically important roles in various organs through second ER, namely ER‐β, distributing systemically. In this article, the association of estrogens with these cancers in postmenopausal or elderly women are reviewed, especially focusing on the role of ER‐β and peripheral estrogen metabolism. The possibility of prevention or treatment of these diseases through estrogenic control is also discussed.

[1]  H. Kawai Estrogen receptors as the novel therapeutic biomarker in non-small cell lung cancer. , 2014, World journal of clinical oncology.

[2]  H. Brenner,et al.  Repeat polymorphisms in ESR2 and AR and colorectal cancer risk and prognosis: results from a German population-based case-control study , 2014, BMC Cancer.

[3]  T. Burns,et al.  Targeting the estrogen pathway for the treatment and prevention of lung cancer. , 2014, Lung cancer management.

[4]  M. Muramatsu,et al.  [Association between colorectal cancer and estrogens]. , 2014, Nihon rinsho. Japanese journal of clinical medicine.

[5]  L. Marks,et al.  Lung , 2013, ALERT • Adverse Late Effects of Cancer Treatment.

[6]  Intratumoral localization and activity of 17β-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factor , 2013, Journal of Translational Medicine.

[7]  H. Brenner,et al.  Colorectal cancer risk associated with hormone use varies by expression of estrogen receptor-β. , 2013, Cancer Research.

[8]  Y. Kakeji,et al.  Estrogen receptor‐β gene polymorphism and colorectal cancer risk: Effect modified by body mass index and isoflavone intake , 2013, International journal of cancer.

[9]  N. Shah,et al.  Intracystic papillary carcinoma of breast: report of three cases and review of the literature , 2012, BMJ Case Reports.

[10]  R. Prentice,et al.  Estrogen plus progestin and colorectal cancer incidence and mortality. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Sasano,et al.  Co-expression of estrogen receptor beta and aromatase in Japanese lung cancer patients: gender-dependent clinical outcome. , 2012, Life sciences.

[12]  M. Teh,et al.  Female reproductive factors, gene polymorphisms in the estrogen metabolism pathway, and risk of lung cancer in Chinese women. , 2012, American journal of epidemiology.

[13]  S. Horvath,et al.  Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer. , 2011, Lung cancer.

[14]  J. Cerhan,et al.  Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women , 2011, Gut.

[15]  N. Harada,et al.  Sex steroid hormones in pairs of tumor and serum from breast cancer patients and pathobiological role of androstene‐3β, 17β‐diol , 2011, Cancer science.

[16]  Mamoun Younes,et al.  Oestrogen receptor‐β CA repeat polymorphism is associated with incidence of colorectal cancer among females , 2011, Histopathology.

[17]  G. Vlastos,et al.  Lung cancer mortality risk among breast cancer patients treated with anti‐estrogens , 2011, Cancer.

[18]  M. Inoue,et al.  Plasma Isoflavones and the Risk of Lung Cancer in Women: A Nested Case–Control Study in Japan , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[19]  A. Schatzkin,et al.  Reproductive history and risk of colorectal cancer in postmenopausal women. , 2010, Journal of the National Cancer Institute.

[20]  J. Manson,et al.  Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. , 2010, Journal of the National Cancer Institute.

[21]  S. Batra,et al.  Lung cancer in women: role of estrogens , 2010, Expert review of respiratory medicine.

[22]  M. Sawabe,et al.  Role of methylation of the hMLH1 gene promoter in the development of gastric and colorectal carcinoma in the elderly , 2010, Geriatrics & gerontology international.

[23]  Takashi Suzuki,et al.  In situ estrogen production and its regulation in human breast carcinoma: From endocrinology to intracrinology , 2009, Pathology international.

[24]  T. Aas,et al.  Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status , 2009, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  J. Siegfried,et al.  Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. , 2009, Lung cancer.

[26]  G. Thomas,et al.  Breast cancer in the elderly , 2004 .

[27]  Takashi Suzuki,et al.  Steroid sulfatase and estrogen sulfotransferase in colon carcinoma: regulators of intratumoral estrogen concentrations and potent prognostic factors. , 2009, Cancer research.

[28]  R. Shore,et al.  Postmenopausal Levels of Endogenous Sex Hormones and Risk of Colorectal Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.

[29]  Takuji Iwase,et al.  Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Inoue,et al.  Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Winter,et al.  Oestrogen and the colon: potential mechanisms for cancer prevention. , 2008, The Lancet. Oncology.

[32]  M. Barone,et al.  Estrogens, phytoestrogens and colorectal neoproliferative lesions , 2008, Genes & Nutrition.

[33]  J. Manson,et al.  Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. , 2007, Cancer research.

[34]  E. Halm,et al.  Sex differences in lung cancer survival: do tumors behave differently in elderly women? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  P. Taylor,et al.  Usefulness of Body Mass Index as a Sufficient Adiposity Measurement for Sex Hormone Concentration Associations in Postmenopausal Women , 2006, Cancer Epidemiology Biomarkers & Prevention.

[36]  N. Harada,et al.  Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years. , 2006, The Journal of clinical endocrinology and metabolism.

[37]  A. Potti,et al.  Hormone replacement therapy is associated with decreased survival in women with lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Wolff,et al.  Associations between ERα, ERβ, and AR Genotypes and Colon and Rectal Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[39]  D. Harrison,et al.  ERβ isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates , 2005, The Journal of pathology.

[40]  R. Wolff,et al.  Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[41]  N. Harada,et al.  Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status , 2003, Histopathology.

[42]  V. Beral,et al.  Evidence from randomised trials on the long-term effects of hormone replacement therapy , 2002, The Lancet.

[43]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[44]  L. Melton,et al.  Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. , 2001, The Journal of clinical endocrinology and metabolism.

[45]  J. Potter,et al.  Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. , 2001, Cancer research.

[46]  Y. Ouchi,et al.  Molecular cloning and characterization of human estrogen receptor βcx: A potential inhibitor of estrogen action in human , 1998 .

[47]  Hajime Orimo,et al.  Isolation and radiation hybrid mapping of dinucleotide repeat polymorphism at the human estrogen receptor β locus , 1998, Journal of Human Genetics.

[48]  J. Corton,et al.  Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. , 1998, Endocrinology.

[49]  Y. Ouchi,et al.  Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. , 1998, Nucleic acids research.

[50]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[51]  F. Koerner,et al.  Solid papillary carcinoma of the breast. A form of intraductal carcinoma with endocrine differentiation frequently associated with mucinous carcinoma. , 1995, The American journal of surgical pathology.

[52]  M. Thun,et al.  Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. , 1995, Journal of the National Cancer Institute.

[53]  T. Iwase,et al.  CLINICOPATHOLOGICAL IMAGES OF INTRACYSTIC BREAST CARCINOMA , 1994 .

[54]  E. Wynder,et al.  Re: Endocrine factors and adenocarcinoma of the lung in women. , 1994, Journal of the National Cancer Institute.

[55]  J. Crowley,et al.  Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  R. Hoover,et al.  Risk of cancer in women receiving hormone replacement therapy , 1989, International journal of cancer.

[57]  A. Forrest,et al.  Significance of aromatase activity in human breast cancer. , 1982, Cancer research.